About

What if we could defeat disease?

The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease.

The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning.

Enter Proteovant Therapeutics

Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.

We are pursuing this expansive field with speed, scale and intention. Proteovant integrates its foundational degrader portfolio, extensive internal drug hunting expertise, and VantAI’s proprietary ‘Protein Contact First’ deep learning platform to advance novel protein degraders across a range of therapeutic areas. The acquisition of Oncopia Therapeutics in 2020 provided access to sophisticated degrader design capabilities and a robust patented pipeline.

Additionally, we have the strong backing and life sciences expertise of our lead investor, Roivant Sciences.

Leadership Team

Our team possesses the scientific knowledge, business acumen and risk-tolerance required to unlock the potential of this promising field of science and deliver transformational therapies for patients.

Drew Fromkin

Chief Executive Officer

Ruby Holder, MBA

Chief Strategy Officer

Zhihua Sui, PhD

Chief Scientific Officer

Tiago Girão, CPA

Chief Financial Officer

Larry J. Jolivette, PhD

VP, DMPK

Helai Mohammad, PhD

VP, Biology

Scott Priestley, PhD

VP, Discovery Chemistry

Corey Strickland, PhD

VP, Molecular Technology

Christine Stuhlmiller, MBA

VP, Program Management

Winston Wu, PhD

VP, CMC

Board of Directors

Frank Torti, MD, Chairman
Vant Chair, Roivant Sciences

Eric Venker, MD
President & Chief Operating Officer, Roivant Sciences

Jonggil Choi
Vice President, Bioinvestment Center, SK. Inc.

Investors and Partners

Roivant Sciences develops transformative medicines faster by building technologies and developing talent in creative ways.

SK Inc. boasts globally competitive operating companies in diverse areas such as energy, chemicals, information and communications, materials, logistics and service.

Dr. Shaomeng Wang’s lab at the University of Michigan is focused on the discovery and development of novel small molecule therapeutics, including targeting protein-protein interactions.

VantAI is the world’s leading engine for the computational design and optimization of targeted protein degraders.

Blueprint Medicines and Proteovant Therapeutics entered into a strategic collaboration to advance novel targeted protein degrader therapies. Under the agreement, the companies will discover and advance up to two novel protein degrader target programs into development, with the option to extend to two additional programs.

At Proteovant, we embrace collaboration, internally and externally. We welcome hearing from potential partners, collaborators and parties interested in our platform and pipeline. Please contact us at info@proteovant.com to get in touch.

Dr. Shaomeng Wang’s lab at the University of Michigan is focused on the discovery and development of novel small molecule therapeutics, including targeting protein-protein interactions.